{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"ATLANTIS","nct_id":"NCT02566993","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=atlantis-nct02566993. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ATLANTIS","arms":[{"description":"Lurbinectedin (PM01183) / Doxorubicin","label":"Experimental Arm","type":"EXPERIMENTAL"},{"description":"CAV (Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR))","label":"Control Arm 1","type":"ACTIVE_COMPARATOR"},{"description":"Topotecan","label":"Control Arm 2","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2020-02-24","type":"ACTUAL"},"conditions":["Small-cell Lung Cancer"],"enrollment":{"count":613,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Lurbinectedin (PM01183)","otherNames":[],"type":"DRUG"},{"name":"Doxorubicin (DOX)","otherNames":[],"type":"DRUG"},{"name":"Cyclophosphamide (CTX)","otherNames":[],"type":"DRUG"},{"name":"Vincristine (VCR)","otherNames":[],"type":"DRUG"},{"name":"Topotecan","otherNames":[],"type":"DRUG"}],"last_update":"2021-10-28","lead_sponsor":"PharmaMar","official_title":"Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2020-02-24","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Every three months up to death or study termination, a period of approximately 3.5 years"}],"references":[{"citation":"Aix SP, Ciuleanu TE, Navarro A, Cousin S, Bonanno L, Smit EF, Chiappori A, Olmedo ME, Horvath I, Grohe C, Farago AF, Lopez-Vilarino JA, Cullell-Young M, Nieto A, Vasco N, Gomez J, Kahatt C, Zeaiter A, Carcereny E, Roubec J, Syrigos K, Lo G, Barneto I, Pope A, Sanchez A, Kattan J, Zarogoulidis K, Waller CF, Bischoff H, Juan-Vidal O, Reinmuth N, Domine M, Paz-Ares L. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. Lancet Respir Med. 2023 Jan;11(1):74-86. doi: 10.1016/S2213-2600(22)00309-5. Epub 2022 Oct 14.","pmid":"36252599","type":"DERIVED"}],"start_date":{"date":"2016-08-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT02566993"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/atlantis-nct02566993"}